Valsartan improves adipose tissue function in humans with impaired glucose metabolism: A randomized placebo-controlled double-blind trial

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Goossens, Gijs H ^a   Moors, Chantalle C M ^a   van der Zijl, Nynke J ^b   Venteclef, Nicolas ^c   Alili, Rohia ^c   Jocken, Johan W E ^a   Essers, Yvonne ^a   Cleutjens, Jack P ^d   Clément, Karine ^c   Diamant, Michaela ^b   Blaak, Ellen E ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; LECTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN; XENON 133;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOGENESIS; ADULT; ANGIOGENESIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; IMPAIRED GLUCOSE METABOLISM; INFLAMMATION; INSULIN SENSITIVITY; LIPOLYSIS; MACROPHAGE MIGRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT DURATION;

ADIPOCYTES; ADIPOSE TISSUE; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CAPILLARIES; CELL HYPOXIA; CELL SIZE; CHEMOTACTIC FACTORS; DOUBLE-BLIND METHOD; FASTING; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; INFLAMMATION; INSULIN; LIPOLYSIS; MACROPHAGES; MALE; MIDDLE AGED; PLACEBOS; POSTPRANDIAL PERIOD; TETRAZOLES; VALINE;

RODENTIA;

EID: 84863113881     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039930     Document Type: Article

References (39)

1. Goossens GH, Blaak EE, van Baak MA, (2003) Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 4: 43-55.
2. Henriksen EJ, (2007) Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 293: R974-980.
3. Leung PS, (2007) Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes. Diabet Med 24: 110-116.
4. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR, (2009) Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 302: 128-139.
5. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI, (2005) The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes. Diabetes Care 28: 2261-2266.
6. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, et al. (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362: 1477-1490.
7. Goossens GH, Blaak EE, Schiffers PM, Saris WH, van Baak MA, (2006) Effect of short-term ACE inhibitor treatment on peripheral insulin sensitivity in obese insulin-resistant subjects. Diabetologia 49: 3009-3016.
8. Goossens GH, (2008) The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 94: 206-218.
9. Chu KY, Lau T, Carlsson PO, Leung PS, (2006) Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55: 367-374.
10. Cole BK, Keller SR, Wu R, Carter JD, Nadler JL, et al. (2010) Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 55: 715-721.
11. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, et al. (2004) Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 22: 1977-1982.
12. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, et al. (2006) Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70: 1717-1724.
13. Munoz MC, Giani JF, Dominici FP, Turyn D, Toblli JE, (2009) Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens 27: 2409-2420.
14. Tomono Y, Iwai M, Inaba S, Mogi M, Horiuchi M, (2008) Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens 21: 206-212.
15. van der Zijl NJ, Moors CC, Goossens GH, Hermans MM, Blaak EE, et al. (2011) Valsartan Improves {beta}-Cell Function and Insulin Sensitivity in Subjects with Impaired Glucose Metabolism: A randomized controlled trial. Diabetes Care 34: 845-851.
16. Nissen SE, Wolski K, (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
17. Jocken JW, Langin D, Smit E, Saris WH, Valle C, et al. (2007) Adipose triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state. J Clin Endocrinol Metab 92: 2292-2299.
18. Zandbergen F, Mandard S, Escher P, Tan NS, Patsouris D, et al. (2005) The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem J 392: 313-324.
19. Goossens GH, McQuaid SE, Dennis AL, van Baak MA, Blaak EE, et al. (2006) Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans. J Physiol 571: 451-460.
20. Samra JS, Frayn KN, Giddings JA, Clark ML, Macdonald IA, (1995) Modification and validation of a commercially available portable detector for measurement of adipose tissue blood flow. Clin Physiol 15: 241-248.
21. DeFronzo RA, Tobin JD, Andres R, (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214-223.
22. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, et al. (2005) Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 1: 107-119.
23. Hausman GJ, Richardson RL, (2004) Adipose tissue angiogenesis. J Anim Sci 82: 925-934.
24. Taleb S, Clement K, (2007) Emerging role of cathepsin S in obesity and its associated diseases. Clin Chem Lab Med 45: 328-332.
25. Yang X, Lu X, Lombes M, Rha GB, Chi YI, et al. (2010) The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab 11: 194-205.
26. Goossens GH, Blaak EE, Saris WH, Van Baak MA, (2004) Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J Clin Endocrinol Metab 89: 2690-2696.
27. Goossens GH, Bizzarri A, Venteclef N, Essers Y, Cleutjens JP, et al. (2011) Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation 124: 67-76.
28. Goossens GH, Jocken JW, Blaak EE, Schiffers PM, Saris WH, et al. (2007) Endocrine role of the renin-angiotensin system in human adipose tissue and muscle: effect of beta-adrenergic stimulation. Hypertension 49: 542-547.
29. Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LK, et al. (2002) Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 51: 2467-2473.
30. Samra JS, Simpson EJ, Clark ML, Forster CD, Humphreys SM, et al. (1996) Effects of epinephrine infusion on adipose tissue: interactions between blood flow and lipid metabolism. Am J Physiol 271: E834-839.
31. Edens NK, Leibel RL, Hirsch J, (1990) Mechanism of free fatty acid re-esterification in human adipocytes in vitro. J Lipid Res 31: 1423-1431.
32. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, et al. (2009) Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 58: 718-725.
33. Jiang BH, Semenza GL, Bauer C, Marti HH, (1996) Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271: C1172-1180.
34. Lundgren M, Svensson M, Lindmark S, Renstrom F, Ruge T, et al. (2007) Fat cell enlargement is an independent marker of insulin resistance and 'hyperleptinaemia'. Diabetologia 50: 625-633.
35. Aksnes TA, Seljeflot I, Torjesen PA, Hoieggen A, Moan A, et al. (2007) Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism 56: 1470-1477.
36. Pscherer S, Heemann U, Frank H, (2010) Effect of Renin-Angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance. Diabetes Care 33: 914-919.
37. Fliser D, Buchholz K, Haller H, (2004) Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110: 1103-1107.
38. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM, (2002) Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51: 1699-1707.
39. Jones BH, Standridge MK, Moustaid N, (1997) Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 138: 1512-1519.